focus -WSS

focus

author：explore 2025-10-01 02:12:15 - browse：639

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Study points to new risk in gene therapy death of Terry Horgan

leisure time

WSS

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Late stage cancers on the rise after pandemic delayed screenings

FDA scientists endorse Pfizer/BioNTech Covid

A controversial new treatment promises to make little people taller

The stability of $0 premiums in Medicare Advantage

How to ethically and practically extend health care to all

focus

focus

leisure time

Medicare details structure of new drug price negotiation program

Heart disease in astronauts blamed on cosmic radiation

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Cancer drug shortages should be causing more outrage

Late stage cancers on the rise after pandemic delayed screenings

ChatGPT in medicine: STAT answers readers' burning questions

New oral drug delivery patch is modeled after octopus tentacles

Medical leaders decry Supreme Court decision on affirmative action

The cancer stories no one wants to hear

focus

FDA approves Sage Therapeutics’ rapid

It costs an awful lot of money to give away a kidney

RSV injection headlines need to be accurate for good uptake

Stop Congress from blocking public access to science

IVG is promising — but it won’t replace IVF quite yet

The cancer stories no one wants to hear

hotspot

leisure time

focus

leisure time